Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2–3% of the world’s population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory parameters such as C-reactive protein (CRP), cytokines and homocysteine, which vary with disease activity. The objective of this clinical study was to investigate the effect of GLP-1 receptor agonist semaglutide therapy on pro-inflammatory factors in the serum and the severity of the clinical picture of psoriasis in obese patients with type 2 diabetes mellitus (T2DM) on chronic metformin therapy. This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16). The results demonstrated that the severity of the clinical picture of psoriasis, determined by the Psoriasis Area and Severity Index (PASI) score, was significantly better after the administration of semaglutide (the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; p = 0.002). Also, the quality of life in the group of patients who received the drug, measured by the Dermatology Life Quality Index (DLQI), improved significantly after 3 months (a median baseline DLQI score in the semaglutide group was 14 (IQR = 5) at the beginning of the study, and after 12 weeks of treatment the median DLQI score was 4 (IQR = 4; p = 0.002)). The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values (p < 0.05). A significant decrease in the body mass index (BMI) value in the semaglutide-treated group was also identified, as well as a significant decrease in the level of low-density cholesterol (LDL) (p < 0.05). In conclusion, semaglutide, based on its systemic anti-inflammatory characteristics, could contribute to the treatment of psoriatic obese patients with T2DM.

Background: Skin aging is influenced by intrinsic and extrinsic factors that alter skin texture and microrelief. Non-invasive imaging techniques enable objective longitudinal assessment of these characteristics. This study aimed to instrumentally and subjectively evaluate skin surface changes during a standardized 90-day dermocosmetic regimen containing multiple active ingredients. Methods: This prospective, single-arm observational study included 47 women aged 30–60 years with visible signs of facial skin aging. Participants applied a standardized anti-age serum and cream regimen twice daily for 90 days. Skin surface morphology was assessed at baseline and after 30, 60, and 90 days using Visioscan^® VC 20plus imaging with SELS^® software. Subjective outcomes were evaluated using a structured product questionnaire and the validated Skindex-16 instrument. Results: Significant temporal changes were observed across objective skin surface parameters. From baseline to day 90, mean skin roughness decreased from 4.99 ± 2.29 to 1.66 ± 0.67, while the wrinkle-related parameter decreased from 191.08 ± 87.26 to 74.27 ± 15.25. Reductions were also observed in scaliness, contrast, entropy, variance, and anisotropy, whereas smoothness, homogeneity, and energy increased over time. Skindex-16 scores decreased across Symptoms, Emotions, and Functioning domains, indicating lower participant-reported dermatology-related burden. The regimen was well tolerated, with no serious adverse events reported. Conclusions: In this exploratory single-arm observational study, the standardized dermocosmetic regimen was associated with measurable longitudinal changes in Visioscan-derived skin surface parameters and patient-reported outcomes over 90 days. Because the study included no control group, the findings cannot establish causality or isolate the contribution of individual regimen components.